In vitro anticancer activity of Bilwadi Agada on colon cancer cell line COLO 205 using sulforhodamine B assay

Abstract Context: Cancer is a group of diseases that occurs when abnormal cells grow uncontrollably or spread to other parts of the body. Despite the fact that contemporary science has developed powerful anticancer medications like Adriamycin, there are many negative side effects. Bilwadi Agada is an herbal drug possessing thirteen ingredients, among which many are proven to have anticancer activity; therefore, the goal of the current study is to use the Sulforhodamine B (SRB) assay to screen that Bilwadi Agada has anticancer potential on colon cancer cell line COLO 205. Materials and Methods: Bilwadi Agada was prepared by powdering thirteen ingredients and subjecting them to Bhavana (trituration) using Goat’s urine. Hydroalcoholic extracts from Bilwadi Agada were prepared. SRB assay was performed to investigate the cell viability in colon cancer cell line COLO 205 after sample treatment. Results: Inhibitory average results of Bilwadi Agada were 69.6, 62.3, 73.0, and 96.4 as against Adriamycin results 0.1, −4.5, 4.7, 21.4 for 10, 20, 40, 80 μg/ml concentration, respectively. Discussion: Bilwadi Agada showed moderate inhibitory activity in a concentration-dependent manner as against Adriamycin. Conclusion: Bilwadi Agada showed moderate anticancer activity against COLO205 cells, but its efficacy was limited compared to Adriamycin. Further studies are warranted to enhance its potency.